PE-22-28.
About PE-22-28
PE-22-28 is studied in tissue regeneration and repair research, including cell and animal models. Selectively and more potently than parent spadin blocks the TREK-1 potassium channel (a target implicated in depression), showing improved in vivo stability and antidepressant-like activity in rodent models.
Research Application
Studied preclinically for rapid-onset antidepressant-like effects and promotion of hippocampal neurogenesis and synaptogenesis; animal-model data only, no published human efficacy trials.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
Studies on regenerative peptides are mostly derived from cell culture and animal models; comprehensive clinical data is typically still limited.
- Mazella J, et al. PLoS Biol. 2010;8(4):e1000355. PMID 20405001
- Devader C, et al. Br J Pharmacol. 2015;172(10):2604–2617. PMID 25598009
- Djillani A, et al. Front Pharmacol. 2017;8:643. PMID 28955242
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Similar Peptides
Question about PE-22-28?
We reply personally – via email or Telegram.